{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:16:10Z","timestamp":1761621370066,"version":"3.41.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ancard.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T14:47:35Z","timestamp":1520952455000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Facteurs de risque pharmacocin\u00e9tiques de surdosage en b\u00eata-bloquants chez les patients \u00e2g\u00e9s\u00a0: cas clinique et rationnel pharmacologique"],"prefix":"10.1016","volume":"67","author":[{"given":"L.","family":"Lafarge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-J.","family":"Dehan-Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"De La Gastine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ancard.2018.02.001_bib0305","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjcard.2004.11.052","article-title":"Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000\u00a0patients in large-scale clinical trials","volume":"95","author":"Dulin","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2018.02.001_bib0315","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/CIR.0b013e31821daaf6","article-title":"ACCF\/AHA 2011\u00a0expert consensus document on hypertension in the elderly\u00a0: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"123","author":"Aronow","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ancard.2018.02.001_bib0320","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.exger.2004.05.011","article-title":"Drug therapy in the elderly","volume":"39","author":"Turnheim","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0325","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2125.1985.tb05072.x","article-title":"A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects","volume":"20","author":"Rigby","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0330","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejheart.2004.01.015","article-title":"Beta-blocker induced bradycardia-should we pace?","volume":"6","author":"Hoppe","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ancard.2018.02.001_bib0335","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1021\/ci300367a","article-title":"admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties","volume":"52","author":"Cheng","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.ancard.2018.02.001_bib0340","unstructured":"Genophar II Working group. DDI-Predictor. Available at http:\/\/www.ddi-predictor.org\/. Accessed 05 March 2018."},{"key":"10.1016\/j.ancard.2018.02.001_bib0345","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2125.2005.02489.x","article-title":"Effects of grapefruit juice on the pharmacokinetics of acebutolol","volume":"60","author":"Lilja","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0350","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1248\/bpb.29.846","article-title":"Transport of acebutolol through rabbit corneal epithelium","volume":"29","author":"Kawazu","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ancard.2018.02.001_bib0355","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2125.1977.tb00779.x","article-title":"Acebutolol metabolite plasma concentration during chronic oral therapy","volume":"4","author":"Winkle","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1983.tb02158.x","article-title":"Acebutolol pharmacokinetics in renal failure","volume":"16","author":"Smith","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0365","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/j.1552-4604.1992.tb03820.x","article-title":"Effect of aging on the pharmacokinetics of acebutolol enantiomers","volume":"32","author":"Piquette-Miller","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0370","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1742-7843.2005.pto_223.x","article-title":"Effect of itraconazole on the pharmacokinetics of atenolol","volume":"97","author":"Lilja","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0375","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00228-005-0930-9","article-title":"Effects of orange juice on the pharmacokinetics of atenolol","volume":"61","author":"Lilja","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0380","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1742-7843.2006.pto_379.x","article-title":"Effect of rifampicin on the pharmacokinetics of atenolol","volume":"98","author":"Lilja","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0385","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/clpt.1980.166","article-title":"Atenolol kinetics in renal failure","volume":"28","author":"McAinsh","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ancard.2018.02.001_bib0390","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2125.1980.tb01065.x","article-title":"Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis","volume":"9","author":"Flouvat","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0395","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1472-8206.2007.00518.x","article-title":"Association of CYP2D6\u00a0and ADRB1\u00a0genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension","volume":"21","author":"Zateyshchikov","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0400","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1472-8206.2006.00408.x","article-title":"Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein","volume":"20","author":"Bachmakov","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/js970316d","article-title":"Pharmacokinetics and metabolism of bisoprolol enantiomers in humans","volume":"87","author":"Horikiri","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ancard.2018.02.001_bib0410","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00870987","article-title":"Interaction of bisoprolol with cimetidine and rifampicin","volume":"31","author":"Kirch","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00003088-198917010-00005","article-title":"Population pharmacokinetic analysis of bisoprolol","volume":"17","author":"Grevel","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ancard.2018.02.001_bib0420","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ancard.2018.02.001_bib0425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clpt.2003.10.004","article-title":"CYP2D6\u00a0genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects","volume":"75","author":"Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ancard.2018.02.001_bib0430","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1074248410372926","article-title":"The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics","volume":"15","author":"Stout","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ancard.2018.02.001_bib0435","first-page":"970","article-title":"In vitro identification of the human cytochrome p450\u00a0enzymes involved in the metabolism of R(+)- and S(-)-carvedilol","volume":"25","author":"Oldham","year":"1997","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.ancard.2018.02.001_bib0440","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002280050628","article-title":"The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency","volume":"55","author":"Gehr","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0445","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1476-5381.1993.tb13914.x","article-title":"Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein","volume":"110","author":"Karlsson","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0450","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00228-003-0694-z","article-title":"Rifampicin reduces plasma concentrations of celiprolol","volume":"59","author":"Lilja","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0455","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00316098","article-title":"Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function","volume":"39","author":"Hartmann","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0460","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2165\/00003088-199528030-00002","article-title":"Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics","volume":"28","author":"Wiest","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ancard.2018.02.001_bib0465","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.1989.35","article-title":"Pharmacokinetics of esmolol and ASL-8123\u00a0in renal failure","volume":"45","author":"Flaherty","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ancard.2018.02.001_bib0470","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jps.20639","article-title":"Labetalol absorption kinetics: rat small intestine and colon studies","volume":"95","author":"Abushammala","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ancard.2018.02.001_bib0475","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/j.1552-4604.1992.tb03823.x","article-title":"Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine","volume":"32","author":"Hermann","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0480","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00007691-199206000-00006","article-title":"Bioavailability of labetalol in patients with end-stage renal disease","volume":"14","author":"Luke","year":"1992","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ancard.2018.02.001_bib0485","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2013.193","article-title":"An investigation of CYP2D6\u00a0genotype and response to metoprolol CR\/XL during dose titration in patients with heart failure: a MERIT-HF substudy","volume":"95","author":"Batty","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ancard.2018.02.001_bib0490","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0091270010365559","article-title":"Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine","volume":"51","author":"Stout","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0495","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004714-200702000-00005","article-title":"Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6\u00a0function in healthy volunteers","volume":"27","author":"Preskorn","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0500","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1177\/0091270005281816","article-title":"Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients","volume":"45","author":"Cerqueira","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0505","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.molpharmaceut.5b00733","article-title":"The Nonmetabolized \u03b2-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and P-glycoprotein, but not of OATP1B1\u00a0and OATP1B3","volume":"2","author":"Misaka","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ancard.2018.02.001_bib0510","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jcph.95","article-title":"Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers","volume":"53","author":"Misaka","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ancard.2018.02.001_bib0515","doi-asserted-by":"crossref","first-page":"227S","DOI":"10.1111\/j.1365-2125.1979.tb04694.x","article-title":"Elimination of nadolol by patients with renal impairment","volume":"7","author":"Herrera","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0520","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0091270010370846","article-title":"Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies","volume":"51","author":"Lindamood","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0525","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2006.02796.x","article-title":"The influence of CYP2D6\u00a0phenotype on the clinical response of nebivolol in patients with essential hypertension","volume":"63","author":"Lefebvre","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0530","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/phrs.1998.0387","article-title":"Pharmacology of nebivolol","volume":"38","author":"Mangrella","year":"1998","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ancard.2018.02.001_bib0535","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ancard.2018.02.001_bib0540","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0002-8703(82)90126-0","article-title":"Pharmacokinetics of pindolol in humans and several animal species","volume":"104","author":"Schwarz","year":"1982","journal-title":"Am Heart J"},{"key":"10.1016\/j.ancard.2018.02.001_bib0545","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/j.1552-4604.1977.tb05643.x","article-title":"Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function","volume":"17","author":"Lavene","year":"1977","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0550","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/j.1552-4604.1989.tb03373.x","article-title":"Interaction between propranolol and propafenone in healthy volunteers","volume":"29","author":"Kowey","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0555","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0090-9556(24)15081-7","article-title":"Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s","volume":"28","author":"McGinnity","year":"2000","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.ancard.2018.02.001_bib0560","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00003088-197601050-00004","article-title":"Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment","volume":"1","author":"Bianchetti","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ancard.2018.02.001_bib0565","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2125.1980.tb01068.x","article-title":"Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol","volume":"9","author":"Pirttiaho","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ancard.2018.02.001_bib0570","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/eurheartj\/14.suppl_H.30","article-title":"Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol","volume":"14","author":"Funck-Brentano","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2018.02.001_bib0575","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/j.1875-9114.1982.tb04521.x","article-title":"Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects","volume":"2","author":"Golightly","year":"1982","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ancard.2018.02.001_bib0580","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/0024-3205(91)90341-8","article-title":"The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6\u00a0oxidation by beta-blocking agents in vitro","volume":"48","author":"Ferrari","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.ancard.2018.02.001_bib0585","unstructured":"Agence Nationale de la s\u00e9curit\u00e9 du m\u00e9dicament. Principaux cytochromes (CYP), principes actifs \u00e0 marge th\u00e9rapeutique \u00e9troite et m\u00e9tabolis\u00e9s par ces CYP, inhibiteurs et inducteurs. http:\/\/ansm.sante.fr\/Dossiers\/Interactions-medicamenteuses\/Interactions-medicamenteuses-et-cytochromes\/(offset)\/1. [Accessed 05 March 2018]."},{"key":"10.1016\/j.ancard.2018.02.001_bib0590","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jama.287.3.337","article-title":"Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey","volume":"287","author":"Kaufman","year":"2002","journal-title":"JAMA"},{"volume":"2","year":"2012","author":"Bohler","key":"10.1016\/j.ancard.2018.02.001_bib0595"},{"key":"10.1016\/j.ancard.2018.02.001_bib0300","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archinte.162.4.405","article-title":"Implications of cytochrome P450\u00a0interactions when prescribing medication for hypertension","volume":"162","author":"Flockhart","year":"2002","journal-title":"Arch Intern Med"}],"container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392818300192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392818300192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:28:38Z","timestamp":1751484518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003392818300192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0003392818300192"],"URL":"https:\/\/doi.org\/10.1016\/j.ancard.2018.02.001","relation":{},"ISSN":["0003-3928"],"issn-type":[{"type":"print","value":"0003-3928"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Facteurs de risque pharmacocin\u00e9tiques de surdosage en b\u00eata-bloquants chez les patients \u00e2g\u00e9s\u00a0: cas clinique et rationnel pharmacologique","name":"articletitle","label":"Article Title"},{"value":"Annales de Cardiologie et d'Ang\u00e9iologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ancard.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}